The collaboration of two strong partners, CELLINK and UPM, builds confidence in making these treatments into an industrial and clinical standard, applied in a wider setting instead of remaining only within few hospitals.
Intrarosa will not only expand and strengthen our product portfolio into Women's Health in Canada but will cater to satisfy the unmet medical needs.
Vivimed strategy is to increase its share of Branded products in CIS Markets.
Candid Powder brand is a market-leader in its category, with a market share of 64% in the medicated powder category.
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
The consideration to be paid will be AUD 2.0 mn for 12.5% stake.
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
The price increases are due to the rising costs of raw materials.
Tiger can no longer make an important biotin intermediate using a DSM patented process.
PEL will explore the PLI scheme and apply if its beneficial.
Subscribe To Our Newsletter & Stay Updated
